Default company panoramic image

MedicaMetrix, Inc.

ProstaGlove improves outcomes and saves $ billions by enabling PSA Density to ID men at high risk for aggressive prostate cancer

  • Stage Prototype Ready
  • Industry Medical Devices and Equipment
  • Location Wayland, MA, USA
  • Currency USD
  • Founded January 2004
  • Employees 2
  • Website

Company Summary

ProstaGlove allows low cost measurement of prostate volume during a digital rectal exam, enabling calculation PSA Density, a much better marker for men at high risk of aggressive prostate cancer than PSA alone. ProstaGlove will create a net savings of billions of dollars annually in the US from avoided, unnecessary, prostate biopsies and reduced overtreatment of indolent prostate cancer.


  • Default avatar
    Christopher G. LaFarge
    CEO & Chairman

    Christopher LaFarge is the Founder, CEO, and Chairman of MedicaMetrix. He is a serial entrepreneur who has successfully built 4 companies. He is a results-focused, senior executive with general management experience at board, P&L, and operational levels. Christopher spent 3 years doing biomedical research at Harvard Medical School/Beth Israel Hospital in Boston. Christopher received his BA in Biology from Harvard, and an MBA and an MFS from Yale.

  • Default avatar
    Richard L. Trembowicz

    Richard L. Trembowicz specializes in healthcare finance and has served as founder/senior executive including VP Business Dev., Celtic Insurance, a subsidary of Centene (NYSE: CNC); VP Business Dev. & GC, AMD Telemedicine, Inc., an early-stage medical device company; Partner at Hutchins, Wheeler (now Nixon Peabody) and founded EdTech Networks, Inc., a venture backed company; A.B., Biology, Harvard College; JD, Boston University School of Law.

  • Default avatar
    Ute E. Schwiderski
    VP Clinical R&D and Biometrics

    Ute served as VP Biostatistics and Data Management, Indevus Pharmaceuticals, where she was responsible for project planning and management, biostatistics, statistical programming, data management, medical writing and document review functions. At Bristol-Myers Squibb Ute served as Associate Director, Anti-Infective Biostatistics, and as Manager, CNS Biostatistics. She has a Ph.D., Medical College of Virginia; B.S., Mathematics, U. of Virginia.

  • Default avatar
    I. Peter Kellett
    Director, Product Development

    Peter Kellett is an electrical engineer with 35 years experience in electronics design and manufacture in USA and Europe. Mr. Kellett holds five patents in the fields of telecommunications, control and measurement. Born and educated in the UK, Mr. Kellett lived and worked in France before immigrating to the US in 1970. He founded Product Resources, Inc., an electronics design and manufacturing company in Beverly Mass. BSEE, Lanchester College, UK

  • Default avatar
    David M. Barrett, MD

    Dr. Barrett is a member of the Medical Staff at Dartmouth Hitchcock Med. Ctr. and Professor at Dartmouth Medical School. Dr. Barrett was President, Trustee and CEO, Lahey Clinic; and Chair of the Board of Governors. Before joining Lahey, Dr. Barrett was Chair of Urology at Mayo Clinic, vice chair of the Board of Governors, Trustee of the Mayo Foundation and a member of its Executive Committee. Dr. Barrett is also a director at C. R. Bard.

  • Default avatar
    Martin G. Sanda, MD

    Dr. Sanda is Director of the Prostate Cancer Center at BIDMC, and is Assoc. Professor at Harvard Medical School. Prior to joining BIDMC, he was a tenured Assoc. Professor and Associate Chair of Urology Research at the University of Michigan. Dr. Sanda leads several NCI-funded studies evaluating quality of life after prostate cancer treatment. He also heads a NIH-funded laboratory investigating prostate cancer immunology and biomarkers.


  • Default avatar
    Nutter McClennen & Fish LLP
    Default avatar
    Moody, Famiglietti & Andronico, LLP

Previous Investors

  • Default avatar
    Founders and Insiders